[Blood Coagulation Disorders During ECMO and LVAD Therapy]

Area of Science:

• Cardiovascular Medicine
• Hematology
• Biomedical Engineering

Background:

• Extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVAD) are critical for severe heart and lung failure.
• These devices significantly benefit patients but are linked to complex bleeding and clotting disorders.

Purpose of the Study:

• To elucidate the multifactorial coagulopathy associated with ECMO and LVAD therapies.
• To identify the causes of thromboembolic and hemorrhagic complications in patients using these devices.

Main Methods:

• Review of mechanisms leading to coagulopathy in ECMO and LVAD patients.
• Discussion of diagnostic tools including viscoelastic point-of-care tests and platelet aggregometry.

Main Results:

• ECMO and LVAD induce coagulopathy through contact activation, platelet interaction with artificial surfaces, and shear forces.
• Heparin use can lead to heparin-induced thrombocytopenia, complicating anticoagulation.
• Platelet defects and acquired von Willebrand disease contribute to bleeding risks.

Conclusions:

• Management of ECMO/LVAD-associated coagulopathy requires understanding its multifactorial nature.
• Individualized treatment based on identified causes of thrombotic or hemorrhagic events is essential.
• Coagulation assays are crucial for diagnosing and guiding therapy.